Wednesday, August 6, 2014

PolySciTech PolyVivo AI10 (PLGA-NH2) and AP082 (PLGA) used to develop hyaluronic acid–ceramide-PLGA nanoparticle for targeted cancer delivery of docetaxel

PolySciTech (www.polyscitech.com) provides a wide array of research polymers and precursors. In a recent publication polyvivo AI10 (PLGA-NH2) was utilized for conjugation to CY5.5-NHS stain to generate a PLGA-CY5.5 and this was mixed with PLGA (AP082) and docetaxel to create drug loaded nanoparticles. These were embedded in ceramic/hyaluronic acid structure to create a targeted nanoparticle. Read more: Park, Ju-Hwan, Jae-Young Lee, Ubonvan Termsarasab, In-Soo Yoon, Seung-Hak Ko, Jae-Seong Shim, Hyun-Jong Cho, and Dae-Duk Kim. "Development of poly (lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid–ceramide-based nanostructure for tumor-targeted drug delivery." International Journal of Pharmaceutics (2014). http://www.sciencedirect.com/science/article/pii/S0378517314005377

“Abstract: A hyaluronic acid–ceramide (HACE) nanostructure embedded with docetaxel (DCT)-loaded poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) was fabricated for tumor-targeted drug delivery. NPs with a narrow size distribution and negative zeta potential were prepared by embedding DCT-loaded PLGA NPs into a HACE nanostructure (DCT/PLGA/HACE). DCT-loaded PLGA and DCT/PLGA/HACE NPs were characterized by solid-state techniques, including Fourier-transform infrared (FT-IR) spectroscopy, differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD). A sustained drug release pattern from the NPs developed was observed and negligible cytotoxicity was seen in NIH3T3 cells (normal fibroblast, CD44 receptor negative) and MDA-MB-231 cells (breast cancer cells, CD44 receptor positive). PLGA/HACE NPs containing coumarin 6, used as a fluorescent dye, exhibited improved cellular uptake efficiency, based on the HA-CD44 receptor interaction, compared to plain PLGA NPs. Cyanine 5.5 (Cy5.5)-labeled PLGA/HACE NPs were injected intravenously into a MDA-MB-231 tumor xenograft mouse model and demonstrated enhanced tumor targetability, compared with Cy5.5-PLGA NPs, according to a near-infrared fluorescence (NIRF) imaging study. Considering these experimental results, the DCT/PLGA/HACE NPs developed may be useful as a tumor-targeted drug delivery system. Keywords: Cancer diagnosis; Docetaxel; Embedding; Hyaluronic acid–ceramide; PLGA nanoparticle; Tumor targeting”


Post a Comment